Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Sirnaomics on Track for 2008 Phase I in China

publication date: Dec 27, 2007
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Sirnaomics of Rockville, MD plans to begin a Phase I trial of its lead drug candidate in China during the year 2008. The molecule, called STP601, uses an RNA interference mechanism to target neovascularization in the eye. If Sirnaomics achieves its goal of starting a trial that soon, it would be a remarkable achievement because Sirnaomics is a very young company – it was formed earlier this year – and it has not depended on in-licensing any technology to speed its forward progress. In an exclusive interview, Dr. Lu, CEO of the company, talks about the future of the company. More details...

Stock Symbol (NYSE: NVS)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...